ceo

Pops landed a spot for the worst CEO in biopharma. He is a nice guy, but the company is tanking, the people that work there are outdated and their clinical is a little misleading. The staff there is not innovative and still stuck in the late 90’s on how things work. Benefits are average...

Merck creates two new executive positions; CCO and CMO. Adam Schechter, President of GHH becomes an advisor to Ken Frazier

Earnings slipped more than 40% in the second quarter of FY2018 for Gilead. The company updated that John F. Milligan will step down as CEO and President. https://news.alphastreet.com/gilead-sciences-q2-2018-earnings-results/

Check this out from Seeking Alpha: https://www.google.com/amp/s/seekingalpha.com/amp/article/4133495-2-small-biopharma-ceos-sacked "I refer, of course, to Egalet (EGLT). It is hard to imagine a company that has done a better job of destroying shareholder value here in 2017 as the chart below...

New leadership for Finance, Research & Development and Manufacturing. Will the new leadership deliver? Also, two senior leaders to resign.

After a seven month long search, Teva appoints Kare Schultz as its new CEO. Remember he had axed 1,000 people or 17% of Lundbeck's workforce when he was its CEO.